Targretin Improves Cognitive and Biological Markers in a Patient with Alzheimer's Disease.
about
Early Treatment Critical: Bexarotene Reduces Amyloid-Beta Burden In SilicoDouble-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease.RXR controlled regulatory networks identified in mouse brain counteract deleterious effects of Aβ oligomers.Neuronally-directed effects of RXR activation in a mouse model of Alzheimer's disease.PPARs in the central nervous system: roles in neurodegeneration and neuroinflammation.A randomized controlled study to evaluate the effect of bexarotene on amyloid-β and apolipoprotein E metabolism in healthy subjects
P2860
Targretin Improves Cognitive and Biological Markers in a Patient with Alzheimer's Disease.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Targretin Improves Cognitive a ...... ient with Alzheimer's Disease.
@en
Targretin Improves Cognitive a ...... ient with Alzheimer's Disease.
@nl
type
label
Targretin Improves Cognitive a ...... ient with Alzheimer's Disease.
@en
Targretin Improves Cognitive a ...... ient with Alzheimer's Disease.
@nl
prefLabel
Targretin Improves Cognitive a ...... ient with Alzheimer's Disease.
@en
Targretin Improves Cognitive a ...... ient with Alzheimer's Disease.
@nl
P2093
P2860
P356
P1476
Targretin Improves Cognitive a ...... ient with Alzheimer's Disease.
@en
P2093
Adrian Ivanoiu
Christian Sindic
Jean-Marie Maloteaux
Jean-Noël Octavea
Laurence Dricot
Lisa Quenon
Nathalie Pierrot
Renaud Lhommel
P2860
P304
P356
10.3233/JAD-150405
P577
2015-09-28T00:00:00Z